دورية أكاديمية
أعرض في EDS

Modulation of the Primary Astrocyte-Enriched Cultures' Oxylipin Profiles Reduces Neurotoxicity.

التفاصيل البيبلوغرافية
العنوان: Modulation of the Primary Astrocyte-Enriched Cultures' Oxylipin Profiles Reduces Neurotoxicity.
المؤلفون: Guryleva MV; Faculty of Bioengineering and Bioinformatics, Moscow Lomonosov State University, 119234 Moscow, Russia., Chistyakov DV; Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia., Lopachev AV; Laboratory of Clinical and Experimental Neurochemistry, Research Center of Neurology, 125367 Moscow, Russia., Goriainov SV; SREC PFUR, Peoples' Friendship University of Russia (RUDN University), 117198 Moscow, Russia., Astakhova AA; Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia., Timoshina YA; Laboratory of Clinical and Experimental Neurochemistry, Research Center of Neurology, 125367 Moscow, Russia.; Biological Department, Lomonosov Moscow State University, 119991 Moscow, Russia., Khutorova AV; Laboratory of Clinical and Experimental Neurochemistry, Research Center of Neurology, 125367 Moscow, Russia.; Biological Department, Lomonosov Moscow State University, 119991 Moscow, Russia., Fedorova TN; Laboratory of Clinical and Experimental Neurochemistry, Research Center of Neurology, 125367 Moscow, Russia., Sergeeva MG; Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia.
المصدر: Metabolites [Metabolites] 2021 Jul 30; Vol. 11 (8). Date of Electronic Publication: 2021 Jul 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101578790 Publication Model: Electronic Cited Medium: Print ISSN: 2218-1989 (Print) Linking ISSN: 22181989 NLM ISO Abbreviation: Metabolites Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel : MDPI
مستخلص: Recently, manipulations with reactive astrocytes have been viewed as a new therapeutic approach that will enable the development of treatments for acute brain injuries and neurodegenerative diseases. Astrocytes can release several substances, which may exert neurotoxic or neuroprotective effects, but the nature of these substances is still largely unknown. In the present work, we tested the hypothesis that these effects may be attributed to oxylipins, which are synthesized from n-3 or n-6 polyunsaturated fatty acids (PUFAs). We used astrocyte-enriched cultures and found that: (1) lipid fractions secreted by lipopolysaccharide (LPS)-stimulated rat primary astrocyte-enriched cultures-possessed neurotoxic activity in rat primary neuronal cultures; (2) both of the tested oxylipin synthesis inhibitors, ML355 and Zileuton, reduce the LPS-stimulated release of interleukin 6 (IL-6) by astrocyte cultures, but only ML355 can change lipid fractions from neurotoxic to non-toxic; and (3) oxylipin profiles, measured by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) from neurotoxic and non-toxic lipid fractions, reveal a group of n-3 docosahexaenoic acid derivatives, hydroxydocosahexaenoic acids (HdoHEs)-4-HdoHE, 8-HdoHE, and 17-HdoHE, which may reflect the neuroprotective features of lipid fractions. Regulating the composition of astrocyte oxylipin profiles may be suggested as an approach for regulation of neurotoxicity in inflammatory processes.
References: Nature. 2014 Jun 5;510(7503):92-101. (PMID: 24899309)
Exp Mol Pathol. 2018 Oct;105(2):190-201. (PMID: 30098318)
Curr Neurovasc Res. 2015;12(4):398-403. (PMID: 26265153)
Adv Nutr. 2015 Sep 15;6(5):513-40. (PMID: 26374175)
Int J Mol Sci. 2020 Nov 02;21(21):. (PMID: 33147798)
Biochem J. 2010 Oct 1;431(1):141-8. (PMID: 20653566)
J Neurosci. 2012 May 2;32(18):6391-410. (PMID: 22553043)
Int J Mol Sci. 2020 Mar 05;21(5):. (PMID: 32150861)
J Cell Biochem. 2010 Jan 1;109(1):30-7. (PMID: 19899109)
Nat Rev Neurosci. 2015 May;16(5):249-63. (PMID: 25891508)
Br J Pharmacol. 2010 Oct;161(3):555-70. (PMID: 20880396)
Noro Psikiyatr Ars. 2019 Sep 05;56(4):288-291. (PMID: 31903039)
Mol Neurobiol. 2018 Oct;55(10):8001-8013. (PMID: 29492849)
J Neuroinflammation. 2007 Oct 15;4:26. (PMID: 17937799)
J Immunol. 2012 May 15;188(10):5132-41. (PMID: 22504638)
Nature. 2017 Jan 26;541(7638):481-487. (PMID: 28099414)
Int J Mol Sci. 2019 Aug 09;20(16):. (PMID: 31405034)
Lipids. 2018 Jan;53(1):103-116. (PMID: 29469960)
Am J Physiol Cell Physiol. 2014 Jul 1;307(1):C39-54. (PMID: 24696140)
Int J Mol Sci. 2018 Jan 02;19(1):. (PMID: 29301276)
J Intern Med. 2019 Sep;286(3):240-258. (PMID: 30565762)
PLoS One. 2018 Aug 17;13(8):e0202424. (PMID: 30118527)
Neuron. 2011 Sep 8;71(5):799-811. (PMID: 21903074)
Biochim Biophys Acta Mol Basis Dis. 2017 Jan;1863(1):1-14. (PMID: 27663722)
Mol Neurobiol. 2014 Oct;50(2):520-33. (PMID: 24395134)
J Biol Chem. 2020 Apr 17;295(16):5307-5320. (PMID: 32161117)
Immunity. 2017 Jun 20;46(6):957-967. (PMID: 28636962)
Mol Aspects Med. 2018 Dec;64:161-168. (PMID: 29572110)
PLoS Comput Biol. 2017 Nov 3;13(11):e1005752. (PMID: 29099853)
Cell Calcium. 2003 Apr;33(4):283-92. (PMID: 12618149)
FEBS J. 2010 Jan;277(1):22-9. (PMID: 19843173)
Arterioscler Thromb Vasc Biol. 2017 Oct;37(10):1828-1839. (PMID: 28775075)
Nat Neurosci. 2021 Mar;24(3):312-325. (PMID: 33589835)
Nat Commun. 2016 Sep 23;7:12859. (PMID: 27659679)
Inflammation. 2010 Oct;33(5):344-52. (PMID: 20204486)
Front Immunol. 2020 Jul 16;11:1416. (PMID: 32765501)
Int J Mol Sci. 2020 Dec 16;21(24):. (PMID: 33339154)
Brain Res. 2001 Jun 15;904(1):167-72. (PMID: 11516426)
Neurochem Int. 2004 Oct;45(5):713-9. (PMID: 15234114)
Biochem Biophys Res Commun. 2018 Jun 2;500(2):204-210. (PMID: 29634926)
Biomed Res Int. 2014;2014:761264. (PMID: 24587990)
Neurochem Int. 2019 Dec;131:104513. (PMID: 31369777)
J Neurosci Res. 2008 Mar;86(4):904-9. (PMID: 17960827)
Neurochem Res. 2016 Feb;41(1-2):243-57. (PMID: 26677076)
J Neurosci Res. 2005 Jul 1;81(1):73-84. (PMID: 15931672)
J Neurosci. 2017 Nov 29;37(48):11731-11743. (PMID: 29109234)
Front Physiol. 2014 May 16;5:186. (PMID: 24904426)
J Neurochem. 2017 Mar;140(5):766-775. (PMID: 28002627)
Front Neurosci. 2017 May 30;11:299. (PMID: 28611577)
J Neurochem. 2005 Feb;92(3):477-86. (PMID: 15659218)
CNS Neurol Disord Drug Targets. 2013 Mar;12(2):191-9. (PMID: 23394536)
Br J Pharmacol. 2003 Jul;139(5):1014-22. (PMID: 12839876)
معلومات مُعتمدة: 19-29-01243 Russian Foundation for Basic Research
فهرسة مساهمة: Keywords: ERK1/2; ML355; Zileuton; astrocytes; interleukin 10 (IL-10); interleukin 6 (IL-6); lipoxygenases; neuroinflammation; neurons; neurotoxicity; oxylipins; toll-like receptors (TLRs)
تواريخ الأحداث: Date Created: 20210826 Latest Revision: 20210831
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8399552
DOI: 10.3390/metabo11080498
PMID: 34436439
قاعدة البيانات: MEDLINE
الوصف
تدمد:2218-1989
DOI:10.3390/metabo11080498